Investing.com - Aadi Bioscience reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Aadi Bioscience announced earnings per share of $-0.6800 on revenue of $4.3M (NYSE:MMM). Analysts polled by Investing.com anticipated EPS of $-0.7700 on revenue of $3.11M.
Aadi Bioscience shares are down 0.45% from the beginning of the year and are trading at $13.4250 , down-from-52-week-high.
Aadi Bioscience shares gained 2.95% in intra-day trade after the report.
Aadi Bioscience follows other major Healthcare sector earnings this month
Aadi Bioscience's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar